Healthcare

Lucence garners $20 mln Series A

Singapore-based Lucence, a genomic medicine company, has secured $20 million in Series A funding. IHH Healthcare led the round.

GreatPoint Ventures leads Series B round for Truvian Sciences

Truvian Sciences, a provider of routine health testing services, has secured $27.1 million in Series B financing. GreatPoint Ventures led the round with participation from other investors that included DNS Capital, Tao Capital Partners and Domain Associates.

Werewolf Therapeutics snags $56 mln Series A

Cambridge, Massachusetts-based Werewolf Therapeutics, an oncology biotherapeutics company, has secured $56 million in Series A financing. MPM Capital and Longwood Fund led the round with participation from Taiho Ventures, Arkin Bio Ventures, UPMC Enterprises and DC Investment Partners. In conjunction with the funding, Werewolf Therapeutics has named Dr Daniel J. Hicklin as president and CEO.

Tissum raises 38.75 mln euros

Tissum said Nov. 20 that it raised 38.75 million euros ($42.78 million) in a series B round of funding. New investors include BNP Paribas Développement, the European Investment Fund (EIF), M&L Investments, ValQuest Partners, while TISSIUM’s returning investors were Bpifrance, CM-CIC Innovation, Cap Décisif Management, Omnes Capital and Sofinnova Partners. Tissium, of Paris, is life sciences company aiming to develop and commercialize a biopolymer platform to address various unmet clinical needs.

GHO Capital Fund II raises 975 mln euros

GHO Capital Fund II LP exceeded its target of 800 million euros

Brighton Park Capital takes majority stake in Relatient

Brighton Park Capital has acquired a majority stake in Franklin, Tennessee-based Relatient, a patient engagement vendor. No financial terms were disclosed. Spurrier Capital Partners served as financial adviser to Relatient on the deal.

CD&R to buy Cynosure

Clayton, Dubilier & Rice said Nov. 20 that it agreed to buy Cynosure LLC from Hologic Inc. In a separate release, Hologic said the total purchase price was $205 million cash, subject to certain closing adjustments. Cynosure makes and markets aesthetic treatment systems for dermatologists, plastic surgeons, medical spas, and other healthcare practitioners.

NexPhase invests in Surgent

NexPhase Capital LP has made an investment in Radnor, Pennsylvania-based Surgent, a provider of end-to-end professional education from pre-licensure to continuing education for accounting, finance and healthcare professionals. No financial terms were disclosed.

Sofinnova sells Breath Therapeutics to Zambon

Sofinnova Partners said July 25 that it has sold Breath Therapeutics to Zambon for up to 500 million euros ($556.9 million), including 140 million euros up front. Breath Therapeutics provides inhalation therapies for severe respiratory diseases.

Five Arrows recaps Averhealth

Five Arrows Capital Partners has recapitalized Richmond, Virginia-based Averhealth, a provider of substance use disorder treatment monitoring, care management and related support services. No financial terms were disclosed.